Related Experiment Video
Updated: Oct 1, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients
1University of California, Los Angeles, CARE Center, Los Angeles, California 90095-1793, USA. rmitsuya@mednet.ucla.edu
Abstract:
The complexity of human immunodeficiency virus (HIV) immunopathogenesis has prompted multiple strategic approaches to re-establish normal immune responses. Highly active antiretroviral therapy (HAART) can control viral replication, but it is unable to restore HIV-specific immunity. Newer approaches for managing HIV infection are focusing on cell-mediated immune responses, including the potential for improved immunologic control over HIV replication. Cytokines, such as interleukin (IL)-2 and IL-12, are being evaluated for their ability to enhance cell-mediated immunity, which is thought to be critical for immunologic control. Initial studies with IL-2 have demonstrated an improvement in CD4 cell counts, and large randomized trials are underway to determine the long-term clinical efficacy of IL-2 in combination with antiretroviral therapy, including HAART. Stimulating the immune response against HIV by use of exogenous (therapeutic vaccination) or endogenous (structured treatment interruption) antigens with or without immune adjuvants or cytokines, such as IL-2, is another approach currently being explored.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Inhibitors of Viral Protein Synthesis
Myocarditis III: Medical Management
Inhibitors of Virion Maturation and Assembly
Cryptococcal Meningitis

